Loading
AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.
AZD4512 is an antibody-drug conjugate developed by AstraZeneca. Its target is CD22 (the sponsor names CD22). The sponsor states: An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page. ClinicalTrials.gov describes the intervention as: AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07123454, plans to enrol 91 participants with primary completion expected 2028-03-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page. Connects to CD22.
1.AZD4512's antibody arm binds CD22 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD4512" OR ABSTRACT:"AZD4512") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD4512, not a curated reading list.
Shares CD22 and the tag pipeline.
Shares Hodgkin lymphoma, AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.